ClinicalTrials.gg
CompletedNCT00097981Updated Apr 7, 2017Results posted

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

A Phase 3 interventional study of Thalidomide and Dexamethasone in Multiple Myeloma, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing liposomal doxorubicin in Multiple Myeloma — none open to participants now, none under way, none of them phase 3. liposomal doxorubicin · Multiple Myeloma.

Enrollment
Largest of 25
225 · median 35
Started
2005
with 3 others
Phase 3
Only one
of the 25
Registered
2nd of 25
by date
Lead sponsor
2 of 25
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 25 studies testing liposomal doxorubicin in Multiple Myeloma, this one has the largest enrollment, is one of 4 that started in 2005, is the only one in phase 3, and was the 2nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 25 studies testing liposomal doxorubicin in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing liposomal doxorubicin in Multiple Myeloma as a file.
02

Study summary

The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.

Read the detailed description

This is a multi-center, open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance) study to compare the safety and effectiveness of Thalidomide + Dexamethasone versus DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone in patients with newly diagnosed multiple myeloma. Treatments are administered in 28-day cycles. Patients will receive 4 to 12 treatment cycles, depending on the response of their multiple myeloma to the treatment (measured according to the European Group for Blood and Marrow Transplant Response Criteria). Patients will have additional tests that include Multiple Gated Acquisition (MUGA) scans or echocardiograms to assess the patients for potential cardiotoxicity that could be related to treatment with DOXIL (doxorubicin HCl liposome injection). Maximum duration of study participation for each participant will be 48 weeks.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Newly diagnosed multiple myeloma
  • Thalidomide
  • Dexamethasone
  • DOXIL
  • Pegylated liposomal hydrochloride doxorubicin injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated, confirmed multiple myeloma (per International Myeloma Working Group [IMWG] criteria
  • (ECOG) status 0-2
  • Adequate (ANC), count and
  • Adequate serum calcium
  • Enrollment in System for Thalidomide Education and Prescribing Safety Program (S.T.E.P.S.)

Exclusion criteria

Exclusion Criteria:

  • No treatment with dexamethasone for multiple myeloma
  • No peripheral neuropathy of Grade 2 or higher
  • No (LVEF) of less than 45 percentage
  • No history of life-threatening thromboembolic events of any kind (ie, myocardial infarction, pulmonary embolism, stroke or others), within 1 year before enrollment in the study
  • No deep vein thrombosis (DVT) within 1 year of enrollment
  • No current anticoagulation for DVT
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Active comparator
    Thalidomide + dexamethasone

    Drug: Thalidomide · Drug: Dexamethasone

  • Experimental
    Thalidomide + dexamethasone + DOXIL

    Drug: Thalidomide · Drug: Dexamethasone · Drug: DOXIL

Interventions

  • Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.

  • Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.

  • DrugDOXIL

    DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.

06

What researchers measure

Primary outcomes

  1. Complete Response Rate: Number of Participants Who Achieved a Complete Response

    Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2.

    Time frame: From Cycle 2 until 28 days following completion of treatment

Secondary outcomes

  1. Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)

    Overall response to study medication is defined as number of participants who acheived a complete response (CR) or partial response (PR) by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

    Time frame: From Cycle 2 until 28 days following completion of treatment

  2. Time to 1st Response

    Time to first response was defined as the interval from date of randomization to date of achieving a partial response (PR) or better according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

    Time frame: From Cycle 2 until 28 days following completion of treatment

  3. Time to Progression

    Time to progression is the interval between the date of randomization until disease progression or death due to progression.

    Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit

  4. Overall Survival: Number of Participants Died Due to Any Cause

    Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit

  5. Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)

    Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit

  6. Engraftment: Number of Participants Who Underwent Engraftment

    Engraftment is the process of transplanted stem cells reproducing new cells.

    Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit

07

Results

Posted Nov 27, 2008

Participant flow

Participant flow — Overall Study
MilestoneThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Started113112
Received study medication110106
Completed712
Not completed106100
Withdrew: Adverse event3144
Withdrew: Withdrawal by subject108
Withdrew: Protocol violation11
Withdrew: Death24
Withdrew: Physician decision71
Withdrew: Disease progression82
Withdrew: Transplant planned2827
Withdrew: Other1913

Outcome measures

PrimaryComplete Response Rate: Number of Participants Who Achieved a Complete Response

Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2.

Time frame:
From Cycle 2 until 28 days following completion of treatment
Reported as:
Number · Participants
Complete Response Rate: Number of Participants Who Achieved a Complete Response
ParticipantsThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Complete Response Rate: Number of Participants Who Achieved a Complete Response58
Statistical analysis
  • Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone · Cochran-Mantel-Haenszel · p = 0.49Stratified by International Prognostic Index (IPI) stage 1,2 and 3
SecondaryOverall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)

Overall response to study medication is defined as number of participants who acheived a complete response (CR) or partial response (PR) by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

Time frame:
From Cycle 2 until 28 days following completion of treatment
Reported as:
Number · Participants
Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)
ParticipantsThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)8176
Statistical analysis
  • Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone · Cochran-Mantel-Haenszel · p = 0.42Stratified by International Prognostic Index (IPI) stage 1,2 and 3
SecondaryTime to 1st Response

Time to first response was defined as the interval from date of randomization to date of achieving a partial response (PR) or better according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.

Time frame:
From Cycle 2 until 28 days following completion of treatment
Reported as:
Median · Days
Time to 1st Response
DaysThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Time to 1st Response44 (37 to 58)58 (44 to 60)
Statistical analysis
  • Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone · Log Rank · p = 0.42
SecondaryTime to Progression

Time to progression is the interval between the date of randomization until disease progression or death due to progression.

Time frame:
From randomization until death or as assessed up to 2 years post last participant last treatment visit
Reported as:
Median · Days
Time to Progression
DaysThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Time to Progression584 (347 to NA)408 (350 to 597)
Statistical analysis
  • Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone · Log Rank · p = 0.5162
SecondaryOverall Survival: Number of Participants Died Due to Any Cause
Time frame:
From randomization until death or as assessed up to 2 years post last participant last treatment visit
Reported as:
Number · Participants
Overall Survival: Number of Participants Died Due to Any Cause
ParticipantsThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Overall Survival: Number of Participants Died Due to Any Cause2122
Statistical analysis
  • Thalidomide + Dexamethasone vs DOXIL + Thalidomide + Dexamethasone · Log Rank · p = 0.93 · Hazard ratio (hr): 0.975 · 95% CI 0.529 to 1.797Stratified log-rank test
SecondaryTransplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)
Time frame:
From randomization until death or as assessed up to 2 years post last participant last treatment visit
Reported as:
Number · Participants
Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)
ParticipantsThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)3028
SecondaryEngraftment: Number of Participants Who Underwent Engraftment

Engraftment is the process of transplanted stem cells reproducing new cells.

Time frame:
From randomization until death or as assessed up to 2 years post last participant last treatment visit
Reported as:
Number · Participants
Engraftment: Number of Participants Who Underwent Engraftment
ParticipantsThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Engraftment: Number of Participants Who Underwent Engraftment2525

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Thalidomide + Dexamethasone—48/110 (43.6%)110/110 (100%)
DOXIL + Thalidomide + Dexamethasone—53/106 (50%)104/106 (98.1%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
PneumoniaInfections and infestations5/1107/106
HyperglycaemiaMetabolism and nutrition disorders7/1101/106
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders6/1104/106
SyncopeNervous system disorders4/1105/106
Renal FailureRenal and urinary disorders5/1103/106
Deep Vein ThrombosisVascular disorders5/1104/106
PyrexiaGeneral disorders1/1104/106
DehydrationMetabolism and nutrition disorders4/1103/106
AnaemiaBlood and lymphatic system disorders2/1103/106
Atrial FibrillationCardiac disorders3/1103/106
Most frequent other events
Showing 10 of 72
Most frequent other events
EventThalidomide + DexamethasoneDOXIL + Thalidomide + Dexamethasone
Oedema PeripheralGeneral disorders53/11060/106
FatigueGeneral disorders58/11058/106
ConstipationGastrointestinal disorders45/11048/106
NauseaGastrointestinal disorders26/11039/106
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders3/11039/106
AnaemiaBlood and lymphatic system disorders21/11031/106
DizzinessNervous system disorders27/11023/106
DyspnoeaRespiratory, thoracic and mediastinal disorders22/11024/106
InsomniaPsychiatric disorders24/11016/106
TremorNervous system disorders20/11022/106

Baseline characteristics

Age, Continuous
Age, Continuous(years)Thalidomide + DexamethasoneDOXIL + Thalidomide + DexamethasoneTotal
Mean60.29 ± 10.3160.62 ± 10.7960.45 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)Thalidomide + DexamethasoneDOXIL + Thalidomide + DexamethasoneTotal
Female514495
Male6268130
08

Study locations

58 sites
  • Fountain Valley, California, United States
  • Greenbrae, California, United States
  • La Verne, California, United States
  • Los Angeles, California, United States
  • Denver, Colorado, United States
  • New London, Connecticut, United States
  • Boca Raton, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orange City, Florida, United States
  • Ormond Beach, Florida, United States
  • Lawrenceville, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Wichita, Kansas, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Minneapolis, Minnesota, United States
  • St Louis Park, Minnesota, United States
  • Columbia, Missouri, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • Englewood, New Jersey, United States
  • Hackensack, New Jersey, United States
  • Jersey City, New Jersey, United States
  • Voorhees, New Jersey, United States
  • Albany, New York, United States
  • Armonk, New York, United States
  • Box 302, New York, United States
  • Bronx, New York, United States
  • Brooklyn, New York, United States
  • Nyack, New York, United States
  • Valhalla, New York, United States
  • Durham, North Carolina, United States
  • Winston Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Eugene, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Wynnewood, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Easley, South Carolina, United States
  • Sumter, South Carolina, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Bedford, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Fredericksburg, Texas, United States
  • Houston, Texas, United States
  • Burlington, Vermont, United States
  • Fairfax, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Spokane, Washington, United States
  • Vancouver, Washington, United States
  • Yakima, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Oct 2007 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2008, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2004
First posted
Dec 2, 2004
Start
Jan 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2009
Results first posted
Nov 27, 2008
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00097981
Collaborators
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Responsible party
Sponsor
First posted
Dec 2, 2004
Start date
Jan 2005
Primary completion
Oct 2007
Completion
Oct 2009
Results posted
Nov 27, 2008
Last update
Apr 7, 2017

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion